The antirheumatic effect of a new nonsteroidal antiinflammatory drug, irritren, a derivative of arylacetic acid namely ionazolac calcium was studied. The favourable effect of irritren treatment in reactivated arthrosis was compared to that of indomethacin. To this end 40 patients were divided into two groups of 20 patients each who were treated for 14 days with: irritren in daily doses of 3 X 200 mg-Group I, and with indomethacin in daily doses of 3 X 25 mg-group II. The results obtained at the end of the experiment showed a marked decrease of joint pain and of inflammation in 85% of the patients in group I while in group II good results were obtained in only 75% of the patients. The excellent digestive tolerance and the absence of untoward side effects situated irritren as clearly superior to indomethacin. The drug appeared as most useful especially in reactivated arthritic diseases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Provision of peri-operative patient blood management strategies in the UK: a national survey of practice.
Anaesthesia
March 2025
NIHR Blood and Transplant Research Unit in Data Driven Transfusion Practice (BTRU), University of Oxford, UK.
Introduction: In UK hospitals, it is unclear how organisational structures are arranged to support effective implementation of peri-operative blood management practice strategies. The aim of this study was to conduct a national survey of organisations to describe local practices of peri-operative patient blood management and infrastructure availability in the UK.
Methods: A series of benchmarking standards was developed using recommendations informed by national standards, relevant literature and an expert panel.
Patterns and indications for quetiapine prescribing in Dutch primary care.
BJGP Open
March 2025
Department of clinical pharmacy, Canisius Wilhelmina Hospital, Utrecht University, Utrecht, The Netherlands
Background: Quetiapine, an antipsychotic, is registered for schizophrenia, bipolar disorder, and as an add-on therapy for major depressive disorder. Its anxiolytic and sedative effects make it attractive for off-label uses like insomnia, despite cardiovascular and metabolic side effects. The global increase in quetiapine use over the past decade warrants an examination of its prescribing patterns, especially off-label.
View Article and Find Full Text PDFHigh-dose oral minoxidil for the treatment of androgenetic alopecia.
Actas Dermosifiliogr
March 2025
Servicio de Dermatología, Unidad de Tricología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España; Unidad de Tricología y Trasplante Capilar, Clínica Grupo Pedro Jaén, Madrid, España.
Low-dose oral minoxidil (≤ 5 mg daily) has emerged as an effective off-label treatment for androgenetic alopecia, outperforming topical minoxidil in terms of adherence. However, the optimal dose has not yet been determined, and high doses may cause systemic adverse effects. This retrospective study of 57 patients evaluated the safety and efficacy profile of oral minoxidil at higher doses (> 5 mg).
View Article and Find Full Text PDFLow-dose ferric carboxymaltose vs. oral iron for improving hemoglobin levels in postpartum East Asian women: A randomized controlled trial.
PLoS One
March 2025
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Ferric carboxymaltose (FCM) is widely used to correct anemia and replenish iron stores rapidly, particularly in Western populations. However, lower doses of FCM are typically used in East Asia, with limited research on their effectiveness, especially in postpartum women. This randomized controlled trial aimed to assess the efficacy of low-dose FCM compared with oral ferrous sulfate in increasing postpartum hemoglobin (Hb) levels and replenishing iron stores in East Asian women.
View Article and Find Full Text PDFEfficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.
J Dermatol
March 2025
Pfizer Japan Inc, Tokyo, Japan.
This subgroup analysis of the ALLEGRO phase 2b/3 study (NCT3732807) assessed the efficacy and safety of multiple doses of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in Asian patients with alopecia areata (AA). Patients aged ≥12 years with AA and ≥50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (with or without 4-week 200-mg loading dose ["200/50" or "200/30"]) or 10 mg or placebo for 24 weeks, followed by a 24-week extension, in which patients initially assigned to placebo switched to 200/50 or 50 mg. In this subgroup analysis, Asian patients with response based on achieving a Severity of Alopecia Tool (SALT) score ≤20, SALT ≤10, ≥2-grade improvement or normal score on the eyebrow assessment (EBA) scale, and ≥2-grade improvement or normal score on the eyelash assessment (ELA) scale were evaluated through week 48.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!